Παρασκευή 12 Μαΐου 2017

Durvalumab reaches PFS endpoint early in phase III trial against NSCLC

Interim analysis of data from the phase III PACIFIC trial of durvalumab to treat non-small-cell lung cancer (NSCLC) in patients who had not progressed following chemo-radiotherapy indicates that the trial has already the primary endpoint of extending...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pGkwYd
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις